Related Experiment Video
Updated: May 20, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
MITF Pathway-Activated Cutaneous Neoplasms
Michael Michal1, Steven D Billings2, Thomas Brenn3
1Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University Plzen, Czech Republic Bioptical Laboratory Ltd, Pilsen, Czech Republic.
Abstract:
Over the past few years, several fusion genes have been reported in dermal-based tumors, resulting in the activation of the microphthalmia (MITF) signalling pathway and a melanocytic phenotype by immunohistochemistry. The best-studied example of these tumors is clear cell sarcoma, which rarely may present as a primary dermal tumor. These tumors are characterized by EWSR1 gene rearrangements, typically with ATF1 and less commonly CREB1. More recently reported cutaneous tumors show gene fusions involving CRTC1::TRIM11, ACTIN::MITF, MITF::CREM, and MED15::ATF1. While the entities in this tumor group share many features, they show subtle distinguishing features, including clinical presentation, histopathologic features, immunophenotype, and outcome. The following overview provides a detailed discussion of these rare tumors with emphasis on differentiating features and differential diagnosis.
Insights
Several dermal tumors activate the microphthalmia (MITF) pathway via gene fusions, leading to a melanocytic phenotype. Understanding these rare tumors, including clear cell sarcoma, is crucial for diagnosis and treatment.
Area of Science:
- Oncology
- Genetics
- Dermatopathology
Background:
- Dermal tumors can exhibit a melanocytic phenotype due to specific gene fusions.
- Microphthalmia (MITF) signaling pathway activation is a common mechanism in these tumors.
- Clear cell sarcoma, characterized by EWSR1 rearrangements, is a well-known example, though rare in the skin.
Purpose of the Study:
- To provide a comprehensive overview of rare dermal tumors with MITF pathway activation.
- To highlight the distinguishing features of various fusion-driven cutaneous tumors.
- To aid in the differential diagnosis of these uncommon neoplasms.
Main Methods:
- Review of recent scientific literature on cutaneous tumors with gene fusions.
- Analysis of characteristic genetic alterations (e.g., EWSR1, CRTC1::TRIM11, ACTIN::MITF).
- Comparison of clinical, histopathologic, and immunophenotypic features.
Main Results:
- Multiple gene fusions (e.g., CRTC1::TRIM11, ACTIN::MITF, MITF::CREM, MED15::ATF1) have been identified in cutaneous tumors.
- These tumors share a melanocytic phenotype and MITF pathway activation.
- Subtle differences in presentation, histology, immunophenotype, and prognosis exist among these entities.
Conclusions:
- Fusion genes play a significant role in the pathogenesis of a subset of rare dermal tumors.
- Accurate differentiation requires careful evaluation of multiple clinicopathologic parameters.
- Further research is needed to fully elucidate the behavior and optimal management of these tumors.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
Mitogens and the Cell Cycle
The Intrinsic Apoptotic Pathway
Abnormal Proliferation